|
AstraZeneca chief executive David Brennan, seen here in March 2007, is delighted with the deal to buy MedImmune for 15.6 billion dollars (11.5 billion euros). The Anglo-Swedish pharmaceuticals giant AstraZeneca told the London Stock Exchange that has entered into a definitive agreement to acquire MedImmune in an all-cash transaction. |